Alpha-1 and Beta-1 adrenergic receptor (α₁- and β₁-adrenergic receptor)

Molecular Classification

G protein-coupled receptor (GPCR), Receptor, Membrane protein

Other Names

Alpha-1 adrenoceptor, α₁-adrenoceptor, Beta-1 adrenoceptor, β₁-adrenoceptor, ADRB1 (gene symbol for Beta-1), ADRA1A, ADRA1B, ADRA1D (gene symbols for Alpha-1 subtypes)

Disease Roles

Cardiovascular disease (e.g., hypertension, heart failure, arrhythmias)InflammationNeurological disorders

Alpha-1 and Beta-1 adrenergic receptor Overview

Alpha-1 and Beta-1 adrenergic receptors are members of the G protein-coupled receptor (GPCR) superfamily that mediate the physiological effects of catecholamines, primarily norepinephrine and epinephrine. Alpha-1 adrenergic receptors are coupled to Gq proteins, leading to activation of phospholipase C and mobilization of intracellular calcium, thereby inducing smooth muscle contraction and vasoconstriction, with important roles in regulating vascular tone and other CNS and peripheral functions[6][5][3][2]. Beta-1 adrenergic receptors are primarily expressed in cardiac tissue, coupled to Gs proteins and stimulating cAMP production, which increases heart rate, myocardial contractility, and renin release[1][7][4]. Antagonists and agonists of these receptors are foundational pharmacological tools in treating cardiovascular and urological disorders, but selectivity is crucial to minimize unwanted side effects[5][1]. Note: For the most structured downstream use, separate entries for "Alpha-1 adrenergic receptor" and "Beta-1 adrenergic receptor" may be advisable, as function, tissue distribution, and drug selectivity differ between the two.

Mechanism of Action

Antagonists: block receptor activation to reduce blood pressure, treat heart failure or benign prostatic hyperplasia Agonists: activate receptors to increase cardiac output (β₁) or induce vasoconstriction (α₁)

Biological Functions

Signal transduction

Regulation of heart rate and cardiac contractility (β₁)

Smooth muscle contraction (α₁)

Vasoconstriction (α₁)

Renin secretion (β₁)

Lipolysis (β₁)

Disease Associations

Cardiovascular disease (e.g., hypertension, heart failure, arrhythmias)

Inflammation

Neurological disorders

Other (e.g., benign prostatic hyperplasia for α₁)

Safety Considerations

Cardiovascular effects (bradycardia, hypotension, exacerbation of heart failure for antagonists; hypertension, tachycardia for agonists)
Orthostatic hypotension (notably for α₁ antagonists)
CNS effects (fatigue, depression, especially for β₁ antagonists)
Bronchospasm (non-selective β antagonists)
Off-target interactions (noted for non-selective or poorly selective agents)

Interacting Drugs

β₁ antagonists: atenolol, metoprolol, bisoprolol, propranolol

β₁ agonists: dobutamine

α₁ antagonists: prazosin, doxazosin, terazosin, tamsulosin

α₁ agonists: phenylephrine, oxymetazoline

Associated Biomarkers

Biomarker
Expression levels of ADRB1 or ADRA1 subtypes may be considered in cardiac or vascular conditions (commonly investigated in research but not widely used clinically); functional response to adrenergic agents is used in diagnostics.